Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

The effect of breakthrough hemolysis on complement factor h and factor I levels in paroxysmal nocturnal hemoglobinuria

Matthew Holt, Daniel Payne, Natalie Fox, Claire McKinley, Morag Griffin, Petra Muus, Talha Munir, Alexandra Pike, Louise Arnold, Sateesh Nagumantry, Richard Kelly, Darren Newton

Blood (2025) 146 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2025-3193

Published: 2025

Journal Articles

Spontaneous remissions in paroxysmal nocturnal hemoglobinuria: True remission or clonal evolution to malignancy?

Caitlin Roger, Matthew Holt, Louise Arnold, Lindsay Mitchell, Sateesh Nagumantry, Katharine Lowndes, Alexandra Pike, Talha Munir, Petra Muus, Morag Griffin, Richard Kelly

Blood (2025) 146 (Supplement 1): 29.

https://doi.org/10.1182/blood-2025-29

Published: 2025

Journal Articles

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Blood (2025) 146 (Supplement 1): 1427.

https://doi.org/10.1182/blood-2025-1427

Published: 2025

Journal Articles

Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.

Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard Kelly, Roochi Trikha, Yasutaka Ueda, Jun-ichi Nishimura, Christopher Patriquin, Alexander Röth, Petra Muus, Jens Panse, Miguel Gómez Álvarez, Alexandra Pike, Talha Munir, Shreyans Gandhi, Austin Kulasekararaj

Blood (2025) 146 (Supplement 1): 1114.

https://doi.org/10.1182/blood-2025-1114

Published: 2025

Journal Articles

The use of anticoagulation on paroxysmal nocturnal hemoglobinuria.

Louise Arnold, Petra Muus, Talha Munir, Alexandra Pike, Sateesh Nagumantry, Hussnain Javaid, Matthew Holt, Elizabeth Littlewood, Amy Todd, Emily Groom-White, Morag Griffin, Richard Kelly

Blood (2025) 146 (Supplement 1): 1111.

https://doi.org/10.1182/blood-2025-1111

Published: 2025

Journal Articles

Factor bb as a biomarker during breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria

Matthew Holt, Daniel Payne, Natalie Fox, Claire McKinley, Morag Griffin, Petra Muus, Talha Munir, Alexandra Pike, Louise Arnold, Sateesh Nagumantry, Darren Newton, Richard Kelly

Blood (2025) 146 (Supplement 1): 4973.

https://doi.org/10.1182/blood-2025-4973

Published: 2025

Journal Articles

Paroxysmal nocturnal hemoglobinuria in pediatric patients: A UK experience

Morag Griffin, Malinthi Adikarama, Shreyans Gandhi, Petra Muus, Alexandra Pike, Talha Munir, Matthew Holt, Louise Arnold, Franceso Versino, Joanna Large, Richard Kelly, Austin Kulasekararaj, Roochi Trikha

Blood (2025) 146 (Supplement 1): 4662.

https://doi.org/10.1182/blood-2025-4662

Published: 2025

Journal Articles

Access to innovative treatment for paroxysmal nocturnal hemoglobinuria in low- and middle-income countries

Andrielle Yost, Mercedes Arteaga, Alicia Annamalay, Catherina Scheepers, Mei Ching Ong, Ines Garcia Gonzalez, Antonio Risitano, Katharine Lowndes, Petra Muus, James Michael Wrigglesworth, Bryan Murphy-Eustis, Pat Garcia-Gonzalez

Blood (2025) 146 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2025-4387

Published: 2025

Journal Articles

A Single-Centre Experience of Methotrexate in the Management of Pure Red Cell Aplasia and Pure White Cell Aplasia

Laura Batey, Richard J. Kelly, Talha Munir, Petra Muus, Abraham Mullasseril Varghese, Louise M Arnold, Catherine Barnfield, Isla Storey, Nora Youngs, Jessica Molyneux, Morag Griffin

Blood (2024) 144 (Supplement 1): 5684.

https://doi.org/10.1182/blood-2024-203945

Published: 2024

Journal Articles

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, John Efthimiou, William Pullman, Hubert Schrezenmeier, Jens Panse

Blood (2024) 144 (Supplement 1): 4072.

https://doi.org/10.1182/blood-2024-205866

Published: 2024

Journal Articles

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Antonio M Risitano, Simona Iacobelli, Austin G. Kulasekararaj, Marleen Van Os, Sophie Terwel, Morag Griffin, Constantijn J.M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Carlos Vallejo, Beatrice Drexler, Jean-Baptiste Méar, Alexander Smith, Emanuele Angelucci, Reinier Raymakers, Marco R De Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda Balari, Isabel Sanchez-Ortega, Blanca Xicoy, Isidro Jarque Ramos, Jamie Cavenagh, Flore Sicre De Fontbrune, Camilla Frieri, Talha Munir, Jennifer Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob Passweg, Sr., Judith Marsh, Gerard Socie, Ghulam Mufti, Carlo Dufour, Regis Peffault De Latour

Blood (2024) 144 (Supplement 1): 302.

https://doi.org/10.1182/blood-2024-194699

Published: 2024

Journal Articles

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Richard J. Kelly, Matthew Holt, Jennifer Vidler, Louise M. Arnold, Joanna Large, Briony Forrest, Catherine Barnfield, Alexandra Pike, Morag Griffin, Talha Munir, Petra Muus, Sateesh K. Nagumantry, Abraham Varghese, John R. Davies, Roochi Trikha, Austin G. Kulasekararaj, Lindsay Mitchell, Shreyans Gandhi

Blood (2024) 143 (12): 1157–1166.

https://doi.org/10.1182/blood.2023021762

Published: 2024

Journal Articles

52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab

Richard J. Kelly, Nicola Houghton, Talha Munir, Petra Muus, Nora Youngs, Lisa Aurand, Kosalai Mohan, Brian Senk, Rodrigo Pavani, Lorah Perlee, Amal Souttou, Morag Griffin

Blood (2023) 142 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2023-188671

Published: 2023

Journal Articles

Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations

Blood (2023) 142 (Supplement 1): 2712.

https://doi.org/10.1182/blood-2023-190393

Published: 2023

Journal Articles

Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations

Alexandra Pike, Stephen John Richards, Claire E McKinley, Louise M Arnold, Abraham Mullasseril Varghese, Talha Munir, Petra Muus, Peter Hillmen, Morag Griffin, Richard J Kelly, Darren Newton

Blood (2023) 142 (Supplement 1): 4097.

https://doi.org/10.1182/blood-2023-188755

Published: 2023

Journal Articles

Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria

Morag Griffin, Petra Muus, Talha Munir, Sateesh Nagumantry, Alexandra Pike, Louise Arnold, Briony Forrest, Catherine Barnfield, Nicola Houghton, Nora Youngs, Richard Kelly

Blood (2023) 141 (1): 116–120.

https://doi.org/10.1182/blood.2022017266

Published: 2023

Journal Articles

A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab

Richard Kelly, Nicola Houghton, Talha Munir, Petra Muus, Nora Youngs, Lisa Aurand, Bradley Dain, Rodrigo Pavani, Lorah Perlee, Amal Souttou, Morag Griffin

Blood (2022) 140 (Supplement 1): 8174–8175.

https://doi.org/10.1182/blood-2022-166547

Published: 2022

Journal Articles

Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom

Richard Kelly, Matthew Holt, Jennifer Vidler, Louise Arnold, Joanna Large, Briony Forrest, Catherine Barnfield, Alexandra Pike, Morag Griffin, Talha Munir, Petra Muus, Sateesh K. Nagumantry, Roochi Trikha, Austin Kulasekararaj, Lindsay Mitchell, Shreyans Ghandi

Blood (2022) 140 (Supplement 1): 5792–5794.

https://doi.org/10.1182/blood-2022-167725

Published: 2022

Journal Articles

Terminal Complement Inhibition and Control of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria Following Switching from High-Dose Eculizumab to Ravulizumab: An Interim Analysis

Morag Griffin, Shreyans Gandhi, Eden Hicks, Deepak Jain, Richard Kelly, Talha Munir, Petra Muus, Masayo Ogawa, Roochi Trikha, Ji Yu, Austin Kulasekararaj

Blood (2022) 140 (Supplement 1): 2928–2930.

https://doi.org/10.1182/blood-2022-159498

Published: 2022

Journal Articles

Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds

Rachael Jones, BSc, Petra Muus, MD PhD, Talha Munir, MBBS, Alexandra Pike, MBBS, Louise Arnold, Jeanifer Gachev, Briony Forrest, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140256

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The effect of breakthrough hemolysis on complement factor h and factor I levels in paroxysmal nocturnal hemoglobinuria

Spontaneous remissions in paroxysmal nocturnal hemoglobinuria: True remission or clonal evolution to malignancy?

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.

The use of anticoagulation on paroxysmal nocturnal hemoglobinuria.

Factor bb as a biomarker during breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria in pediatric patients: A UK experience

Access to innovative treatment for paroxysmal nocturnal hemoglobinuria in low- and middle-income countries

A Single-Centre Experience of Methotrexate in the Management of Pure Red Cell Aplasia and Pure White Cell Aplasia

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab

Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations

Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations

Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria

A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab

Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom

Terminal Complement Inhibition and Control of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria Following Switching from High-Dose Eculizumab to Ravulizumab: An Interim Analysis

Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only